COMPASS Pathways plc

NasdaqGS:CMPS Stock Report

Market Cap: US$318.8m

COMPASS Pathways Valuation

Is CMPS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CMPS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CMPS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CMPS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CMPS?

Key metric: As CMPS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CMPS. This is calculated by dividing CMPS's market cap by their current book value.
What is CMPS's PB Ratio?
PB Ratio1.6x
BookUS$193.03m
Market CapUS$318.84m

Price to Book Ratio vs Peers

How does CMPS's PB Ratio compare to its peers?

The above table shows the PB ratio for CMPS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.8x
CCCC C4 Therapeutics
1.2x-4.0%US$285.9m
JSPR Jasper Therapeutics
3.9x-16.4%US$314.7m
VYGR Voyager Therapeutics
0.9x-29.4%US$292.8m
QURE uniQure
5.1x17.1%US$277.8m
CMPS COMPASS Pathways
1.6x9.8%US$318.8m

Price-To-Book vs Peers: CMPS is good value based on its Price-To-Book Ratio (1.6x) compared to the peer average (2.8x).

Price to Book Ratio vs Industry

How does CMPS's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$507.04m
NKTX Nkarta
0.4x-11.5%US$176.42m
IMAB I-Mab
0.4x1.8%US$79.81m
ACET Adicet Bio
0.4x6.7%US$79.69m
CMPS 1.6xIndustry Avg. 1.8xNo. of Companies84PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CMPS is good value based on its Price-To-Book Ratio (1.6x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is CMPS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CMPS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CMPS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CMPS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.45
US$21.22
+376.9%
67.5%US$60.00US$12.00n/a9
Nov ’25US$4.75
US$24.67
+419.3%
66.7%US$60.00US$12.00n/a9
Oct ’25US$5.96
US$38.22
+541.3%
78.9%US$120.00US$22.00n/a9
Sep ’25US$7.48
US$38.22
+411.0%
78.9%US$120.00US$22.00n/a9
Aug ’25US$6.88
US$38.44
+458.8%
78.6%US$120.00US$22.00n/a9
Jul ’25US$5.95
US$40.38
+578.6%
78.1%US$120.00US$22.00n/a8
Jun ’25US$7.38
US$41.25
+458.9%
75.5%US$120.00US$22.00n/a8
May ’25US$8.48
US$43.86
+417.2%
74.0%US$120.00US$22.00n/a7
Apr ’25US$9.68
US$40.38
+317.1%
78.6%US$120.00US$16.00n/a8
Mar ’25US$11.48
US$41.86
+264.6%
80.4%US$120.00US$16.00n/a7
Feb ’25US$11.34
US$43.00
+279.2%
77.2%US$120.00US$16.00n/a7
Jan ’25US$8.75
US$43.00
+391.4%
77.2%US$120.00US$16.00n/a7
Dec ’24US$6.10
US$45.43
+644.7%
69.8%US$120.00US$22.00n/a7
Nov ’24US$5.78
US$44.50
+669.9%
67.7%US$120.00US$21.00US$4.758
Oct ’24US$7.40
US$44.50
+501.4%
67.7%US$120.00US$21.00US$5.968
Sep ’24US$9.33
US$44.50
+377.0%
67.7%US$120.00US$21.00US$7.488
Aug ’24US$8.95
US$44.89
+401.6%
64.4%US$120.00US$21.00US$6.889
Jul ’24US$8.28
US$42.30
+410.9%
67.4%US$120.00US$19.00US$5.9510
Jun ’24US$7.59
US$42.30
+457.3%
67.4%US$120.00US$19.00US$7.3810
May ’24US$8.08
US$42.30
+423.5%
67.4%US$120.00US$19.00US$8.4810
Apr ’24US$9.93
US$41.55
+318.4%
65.7%US$120.00US$19.00US$9.6811
Mar ’24US$8.13
US$41.55
+411.0%
65.7%US$120.00US$19.00US$11.4811
Feb ’24US$10.61
US$45.91
+332.7%
54.4%US$120.00US$30.00US$11.3411
Jan ’24US$8.03
US$45.91
+471.7%
54.4%US$120.00US$30.00US$8.7511
Dec ’23US$10.22
US$55.09
+439.0%
57.0%US$120.00US$30.00US$6.1011
Nov ’23US$10.65
US$57.60
+440.8%
55.4%US$120.00US$30.00US$5.7810

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.41

7D

0.5%

1Y

17.1%

IQVIA Holdings

US$35.3b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$197.60

7D

-2.6%

1Y

-5.7%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.86

7D

-5.2%

1Y

8.0%